Table 3.
Covariate-adjusted linear regressions of maternal 25(OH)D3 concentrations dichotomized as “sufficient” vs. “insufficient” at 30 ng/mL threshold recommended by the Endocrine Society's 2011 guidelines† and neurodevelopmental outcomes (N = 252).
| Neurodevelopmental outcome measure | Unstandardized beta coefficient | SE | 95% CI | p-value |
|---|---|---|---|---|
| WPPSI-IVCDN FSIQ | −0.12 | 1.97 | −3.97, 3.74 | 0.95 |
| NEPSY-II Phonological Processing | 0.10 | 0.46 | −0.79, 1.00 | 0.82 |
| NEPSY-II Speeded Naming | 0.29 | 0.41 | −0.51, 1.10 | 0.48 |
| MABC-II Total | 0.52 | 0.44 | −0.34, 1.38 | 0.24 |
| BASC-II Internalizing Problems | 1.25 | 1.36 | −1.41, 3.91 | 0.36 |
| BASC-II Externalizing Problems | 0.73 | 1.23 | −1.67, 3.13 | 0.55 |
Covariates are the same as those included in the linear regressions of continuous maternal 25(OH)D3 concentrations and neurodevelopmental outcomes.
The Endocrine Society's 2011 30 ng/mL threshold refers to total 25(OH)D; this total measure could not be calculated in the present study and thus maternal 25(OH)D3 concentrations were used in lieu of the total. These analyses should be a considered a historical sensitivity analysis to improve interpretation across the literature as the 2024 guidelines no longer endorse using this threshold.